{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:37:08Z","timestamp":1794015428261,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Bridge Project, a partnership between the Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber\/Harvard Cancer Center."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76296-8","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:01:30Z","timestamp":1786568490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population-based genomic detection of childhood cancer predisposition using newborn dried blood spots"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-5509","authenticated-orcid":false,"given":"Lisa","family":"Diller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cherkerzian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail E.","family":"Cinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Housman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8643-2725","authenticated-orcid":false,"given":"Riaz","family":"Gillani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla V.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2724-7404","authenticated-orcid":false,"given":"Jennifer M.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arindam","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Parad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"76296_CR1","doi-asserted-by":"publisher","first-page":"101443","DOI":"10.1016\/j.gim.2025.101443","volume":"27","author":"T Minten","year":"2025","unstructured":"Minten, T. et al. Data-driven consideration of genetic disorders for global genomic newborn screening programs. Genet. Med. 27, 101443 (2025).","journal-title":"Genet. Med."},{"key":"76296_CR2","doi-asserted-by":"publisher","first-page":"e2331162","DOI":"10.1001\/jamanetworkopen.2023.31162","volume":"6","author":"T Chen","year":"2023","unstructured":"Chen, T. et al. Genomic sequencing as a first-tier screening test and outcomes of newborn screening. JAMA Netw. Open 6, e2331162 (2023).","journal-title":"JAMA Netw. Open"},{"key":"76296_CR3","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ajhg.2023.05.007","volume":"110","author":"RC Green","year":"2023","unstructured":"Green, R. C. et al. Actionability of unanticipated monogenic disease risks in newborn genomic screening: Findings from the BabySeq Project. Am. J. Hum. Genet. 110, 1034\u20131045 (2023).","journal-title":"Am. J. Hum. Genet."},{"key":"76296_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jama.2024.19662","volume":"333","author":"A Ziegler","year":"2025","unstructured":"Ziegler, A. et al. Expanded newborn screening using genome sequencing for early actionable conditions. JAMA 333, 232\u2013240 (2025).","journal-title":"JAMA"},{"key":"76296_CR5","doi-asserted-by":"crossref","unstructured":"Lunke, S. et al. Feasibility, acceptability and clinical outcomes of the BabyScreen+ genomic newborn screening study. Nat. Med. 12, 4236\u20134245 (2025).","DOI":"10.1038\/s41591-025-03986-z"},{"key":"76296_CR6","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41591-024-03465-x","volume":"31","author":"F Boemer","year":"2025","unstructured":"Boemer, F. et al. Population-based, first-tier genomic newborn screening in the maternity ward. Nat. Med. 31, 1339\u20131350 (2025).","journal-title":"Nat. Med."},{"key":"76296_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jama.2015.10080","volume":"314","author":"RJ Mody","year":"2015","unstructured":"Mody, R. J. et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA 314, 913\u2013925 (2015).","journal-title":"JAMA"},{"key":"76296_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/jamaoncol.2015.5699","volume":"2","author":"DW Parsons","year":"2016","unstructured":"Parsons, D. W. et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2, 616\u2013624 (2016).","journal-title":"JAMA Oncol."},{"key":"76296_CR9","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","volume":"373","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. Germline mutations in predisposition genes in pediatric cancer. N. Engl. J. Med. 373, 2336\u20132346 (2015).","journal-title":"N. Engl. J. Med."},{"key":"76296_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1158\/1940-6207.CAPR-22-0215","volume":"15","author":"SP MacFarland","year":"2022","unstructured":"MacFarland, S. P. et al. Collaboration to promote research and improve clinical care in the evolving field of childhood cancer predisposition. Cancer Prev. Res. (Phila.) 15, 645\u2013652 (2022).","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"76296_CR11","unstructured":"AACR Childhood Cancer Predisposition Workshop Articles. Vol. (American Association for Cancer Research (AACR). https:\/\/www.aacr.org\/professionals\/membership\/scientific-working-groups\/pediatric-cancer-working-group\/aacr-pediatric-cancer-working-group-aacr-childhood-cancer-predisposition-workshop-articles\/ (2025)."},{"key":"76296_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/jmedgenet-2014-102264","volume":"51","author":"CJ Dommering","year":"2014","unstructured":"Dommering, C. J. et al. RB1 mutation spectrum in a comprehensive nationwide cohort of retinoblastoma patients. J. Med. Genet. 51, 366\u2013374 (2014).","journal-title":"J. Med. Genet."},{"key":"76296_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/bjo.2005.089375","volume":"90","author":"SM Imhof","year":"2006","unstructured":"Imhof, S. M., Moll, A. C. & Schouten-van Meeteren, A. Y. Stage of presentation and visual outcome of patients screened for familial retinoblastoma: nationwide registration in the Netherlands. Br. J. Ophthalmol. 90, 875\u2013878 (2006).","journal-title":"Br. J. Ophthalmol."},{"key":"76296_CR14","doi-asserted-by":"publisher","first-page":"15021","DOI":"10.1038\/nrdp.2015.21","volume":"1","author":"H Dimaras","year":"2015","unstructured":"Dimaras, H. et al. Retinoblastoma. Nat. Rev. Dis. Prim. 1, 15021 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"76296_CR15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","volume":"17","author":"A Villani","year":"2016","unstructured":"Villani, A. et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 17, 1295\u20131305 (2016).","journal-title":"Lancet Oncol."},{"key":"76296_CR16","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/s41436-021-01124-x","volume":"23","author":"JM Yeh","year":"2021","unstructured":"Yeh, J. M. et al. Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights. Genet. Med. 23, 1366\u20131371 (2021).","journal-title":"Genet. Med."},{"key":"76296_CR17","doi-asserted-by":"crossref","unstructured":"Gaviglio, A., McKasson, S., Singh, S. & Ojodu, J. Infants with congenital diseases identified through newborn screening-United States, 2018\u20132020. Int. J. Neonatal Screen 9, 23 (2023).","DOI":"10.3390\/ijns9020023"},{"key":"76296_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/ijns11030075","volume":"11","author":"AJ Duintjer","year":"2025","unstructured":"Duintjer, A. J. et al. Comparing DNA Isolation and Preparation Protocolsfor Dried Blood Spots in the Context of Genomic Newborn Screening. Int. J. Neonatal Screen 11, 75 (2025).","journal-title":"Int. J. Neonatal Screen"},{"key":"76296_CR19","doi-asserted-by":"publisher","unstructured":"\u0106avar Pavi\u0107, J. et al. Challenges in identifying paediatric cancer predisposition syndromes: international SCOPE survey and SIOPE expert consensus recommendations. Eur. J. Hum. Genet. https:\/\/doi.org\/10.1038\/s41431-026-02040-x (2026).","DOI":"10.1038\/s41431-026-02040-x"},{"key":"76296_CR20","unstructured":"Michigan BioTrust for Health- Dried Blood Spot Research. Vol. (Michigan Department of Health & Human Services). https:\/\/www.michigan.gov\/mdhhs\/-\/media\/Project\/Websites\/mdhhs\/Public-Health-Genomics\/BioTrust\/Research-Manual-Draft-ADA-Compliant-Final.pdf (2025)."},{"key":"76296_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/gim.2014.117","volume":"17","author":"A Bhattacharjee","year":"2015","unstructured":"Bhattacharjee, A. et al. Development of DNA confirmatory and high-risk diagnostic testing for newborns using targeted next-generation DNA sequencing. Genet. Med. 17, 337\u2013347 (2015).","journal-title":"Genet. Med."},{"key":"76296_CR22","unstructured":"Frise, E. N.-M. et al. Artificial intelligence engine for high-throughput matching of genetic variants to their ACMG\/AMP classification for inherited disease gene panels. https:\/\/cdn2.hubspot.net\/hubfs\/5229318\/Website%20resource%20files%20%5BDO%20NOT%20EDIT%20OR%20DELETE%5D\/ACMG2019\/ACMG2019_an_artificial_intelligence_engine.pdf (2019)."},{"key":"76296_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"76296_CR24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434\u2013443 (2020).","journal-title":"Nature"},{"key":"76296_CR25","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res 46, D1062\u2013d1067 (2018).","journal-title":"Nucleic Acids Res"},{"key":"76296_CR26","unstructured":"R. Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria, https:\/\/www.R-project.org\/ (2021)."},{"key":"76296_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"76296_CR28","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1158\/1078-0432.CCR-24-3271","volume":"31","author":"J Kamihara","year":"2025","unstructured":"Kamihara, J. et al. Update on retinoblastoma predisposition and surveillance recommendations for children. Clin. Cancer Res. 31, 1573\u20131579 (2025).","journal-title":"Clin. Cancer Res."},{"key":"76296_CR29","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.2013.52.6863","volume":"33","author":"JD Wasserman","year":"2015","unstructured":"Wasserman, J. D. et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a Children\u2019s Oncology Group study. J. Clin. Oncol. 33, 602\u2013609 (2015).","journal-title":"J. Clin. Oncol."},{"key":"76296_CR30","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","volume":"23","author":"CP Kratz","year":"2017","unstructured":"Kratz, C. P. et al. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin. Cancer Res. 23, e38\u2013e45 (2017).","journal-title":"Clin. Cancer Res."},{"key":"76296_CR31","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1158\/1078-0432.CCR-24-3301","volume":"31","author":"MI Achatz","year":"2025","unstructured":"Achatz, M. I. et al. Update on cancer screening recommendations for individuals with Li-Fraumeni Syndrome. Clin. Cancer Res. 31, 1831\u20131840 (2025).","journal-title":"Clin. Cancer Res."},{"key":"76296_CR32","doi-asserted-by":"crossref","unstructured":"Mirabello, L. et al. Germline TP53 variants and susceptibility to osteosarcoma. J. Natl. Cancer Inst. 107, djv101 (2015).","DOI":"10.1093\/jnci\/djv101"},{"key":"76296_CR33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/jnci\/djaa204","volume":"113","author":"H Li","year":"2021","unstructured":"Li, H. et al. Germline cancer predisposition variants in Pediatric rhabdomyosarcoma: a report from the children\u2019s oncology group. J. Natl. Cancer Inst. 113, 875\u2013883 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"76296_CR34","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.2009.26.8169","volume":"28","author":"U Tabori","year":"2010","unstructured":"Tabori, U. et al. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J. Clin. Oncol. 28, 1995\u20132001 (2010).","journal-title":"J. Clin. Oncol."},{"key":"76296_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/jmg.2010.083790","volume":"48","author":"I Slade","year":"2011","unstructured":"Slade, I. et al. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J. Med. Genet. 48, 273\u2013278 (2011).","journal-title":"J. Med. Genet."},{"key":"76296_CR36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/1078-0432.CCR-24-1947","volume":"31","author":"KAP Schultz","year":"2025","unstructured":"Schultz, K. A. P. et al. Update on pediatric surveillance recommendations for PTEN hamartoma tumor syndrome, DICER1-related tumor predisposition, and tuberous sclerosis complex. Clin. Cancer Res. 31, 234\u2013244 (2025).","journal-title":"Clin. Cancer Res."},{"key":"76296_CR37","doi-asserted-by":"publisher","unstructured":"Kim, J. et al. Germline pathogenic variants in 786 neuroblastoma patients. medRxiv https:\/\/doi.org\/10.1101\/2023.01.23.23284864 (2023).","DOI":"10.1101\/2023.01.23.23284864"},{"key":"76296_CR38","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1158\/1078-0432.CCR-24-0237","volume":"30","author":"J Kamihara","year":"2024","unstructured":"Kamihara, J. et al. Neuroblastoma predisposition and surveillance-an update from the 2023 AACR childhood cancer predisposition workshop. Clin. Cancer Res. 30, 3137\u20133143 (2024).","journal-title":"Clin. Cancer Res."},{"key":"76296_CR39","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/pbc.20698","volume":"47","author":"S Aretz","year":"2006","unstructured":"Aretz, S. et al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? Pediatr. Blood Cancer 47, 811\u2013818 (2006).","journal-title":"Pediatr. Blood Cancer"},{"key":"76296_CR40","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1158\/1078-0432.CCR-17-0710","volume":"23","author":"JM Kalish","year":"2017","unstructured":"Kalish, J. M. et al. Surveillance recommendations for children with overgrowth syndromes and predisposition to Wilms tumors and hepatoblastoma. Clin. Cancer Res. 23, e115\u2013e122 (2017).","journal-title":"Clin. Cancer Res."},{"key":"76296_CR41","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1200\/JCO.2004.02.136","volume":"22","author":"SE Little","year":"2004","unstructured":"Little, S. E. et al. Frequency and heritability of WT1 mutations in nonsyndromic Wilms\u2019 tumor patients: a UK children\u2019s cancer study group study. J. Clin. Oncol. 22, 4140\u20134146 (2004).","journal-title":"J. Clin. Oncol."},{"key":"76296_CR42","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/jama.1996.03540190047028","volume":"276","author":"C Eng","year":"1996","unstructured":"Eng, C. et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276, 1575\u20131579 (1996).","journal-title":"JAMA"},{"key":"76296_CR43","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1158\/1078-0432.CCR-17-0548","volume":"23","author":"JD Wasserman","year":"2017","unstructured":"Wasserman, J. D. et al. Multiple endocrine neoplasia and hyperparathyroid-jaw tumor syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin. Cancer Res. 23, e123\u2013e132 (2017).","journal-title":"Clin. Cancer Res."},{"key":"76296_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/pbc.22831","volume":"56","author":"KW Eaton","year":"2011","unstructured":"Eaton, K. W., Tooke, L. S., Wainwright, L. M., Judkins, A. R. & Biegel, J. A. Spectrum of SMARCB1\/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr. Blood Cancer 56, 7\u201315 (2011).","journal-title":"Pediatr. Blood Cancer"},{"key":"76296_CR45","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1158\/1078-0432.CCR-17-0595","volume":"23","author":"WD Foulkes","year":"2017","unstructured":"Foulkes, W. D. et al. Cancer surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. Clin. Cancer Res. 23, e62\u2013e67 (2017).","journal-title":"Clin. Cancer Res."},{"key":"76296_CR46","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1470-2045(18)30242-0","volume":"19","author":"SM Waszak","year":"2018","unstructured":"Waszak, S. M. et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 19, 785\u2013798 (2018).","journal-title":"Lancet Oncol."},{"key":"76296_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10689-021-00247-z","volume":"20","author":"L Guerrini-Rousseau","year":"2021","unstructured":"Guerrini-Rousseau, L. et al. Current recommendations for cancer surveillance in Gorlin syndrome: a report from the SIOPE host genome working group (SIOPE HGWG). Fam. Cancer 20, 317\u2013325 (2021).","journal-title":"Fam. Cancer"},{"key":"76296_CR48","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1093\/bioinformatics\/btw325","volume":"32","author":"ZL Skidmore","year":"2016","unstructured":"Skidmore, Z. L. et al. GenVisR: genomic visualizations in R. Bioinformatics 32, 3012\u20133014 (2016).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76296-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76296-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:01:34Z","timestamp":1786568494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76296-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76296"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76296-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8183"}}